A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2005-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was not conducted in the United States. The purpose of this study was to assess the safety and effectiveness of a number of doses of vildagliptin, an unapproved drug, in the treatment of people with type 2 diabetes.

• Phase: Phase 2

Details

• Lead Sponsor: Novartis
• Treatments: Vildagliptin

Criteria

Inclusion Criteria:

• Diagnosis of type 2 diabetes

• Patients who have been placed on diet and exercise therapy without achievement of glycemic control

• Outpatients

Exclusion Criteria:

• Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes

• Significant cardiovascular diseases

• Significant diabetic complications

• Other protocol-defined exclusion criteria may apply